Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...

Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade ... 12 weeks of therapy with adalimumab.

90 Meta-analysis 3493 TNF users versus 1512 RA controls Data from nine randomized clinical trials Infliximab and adalimumab. Identified ten lymphomas cases in anti-TNF treated patients compared ...

has now shown that acquired resistance to anti-TNF therapies differs between agents. The study included 1,198 patients with RA, treated with infliximab, etanercept or adalimumab, identified from ...

A study from Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn’s disease. In this latest study, HLA DQA1*05 positive children just ...

In parallel, experiments performed by the study team also found that the specific protein that adalimumab inhibits, called tumor necrosis factor (TNF), , was potentially playing a key role in iMCD.